ClinicalTrials.gg
Enrolling by invitationNCT07176117SPLASHUpdated Jul 13, 2026

Surfactant Using a Supraglottic Airway Device in Late Preterm to Early Term Infants

An interventional study of Surfactant Administration Through Laryngeal or Supraglottic Airway (SALSA) and Continuous Positive Airway Pressure (CPAP) in Respiratory Distress Syndrome (Neonatal) and Surfactant, sponsored by Sharp HealthCare. Enrolling by invitation at 3 sites in United States. Open to participants aged 33 Weeks to 38 Weeks. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Sharp HealthCare · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
422
Allocation
Randomized
Ages
33 Weeks to 38 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Pulmonary Atelectasis with a site in United States — 11 open to participants now, 11 under way, 1 of them phase 3. Pulmonary Atelectasis · United States.

Planned enrollment
Largest of 37
422 · median 40
Started
2025
with 2 others
No phase
31 of 43
6 open now
Primary completion
2030-12
later than 8 of 10 live
Registered
39th of 43
by date
Lead sponsor
2 of 43
Sharp HealthCare

Among the 43 studies in Pulmonary Atelectasis with a site in United States, this one has the largest planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2025, is one of 31 with no phase, reaches primary completion later than 8 of the 10 other live ones, and was the 39th registered.

Pulmonary Atelectasis

378 studies on the registry are indexed under Pulmonary Atelectasis; 91 are open to participants now.

Browse Pulmonary Atelectasis studies →

Open to participants now

11 of the 43 studies in Pulmonary Atelectasis with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Pulmonary Atelectasis studies recruiting now, 20 (39%) set no upper age limit and 23 (45%) stop at 75 or younger; 24 take children under 18; 2 take healthy volunteers.

This study: 33 Weeks to 38 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Pulmonary Atelectasis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research is to learn new information that may help other infants that have respiratory distress syndrome and need breathing support after birth. The goal of this research is to see if continuous positive airway pressure (CPAP) alone or CPAP with surfactant administration through a less invasive method via an Airway Device (supraglottic airway device) temporarily placed above the vocal cords is better for treating respiratory distress syndrome in late preterm and early term infants.

03

Conditions studied

  • Respiratory Distress Syndrome (Neonatal)
  • Surfactant

Browse trials for

Keywords

  • supraglottic airway device
04

Who can participate

Ages eligible
33 Weeks to 38 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newborns 33-38+6 weeks gestation at birth
  • ≤ 6 hours old
  • Respiratory Distress: [Silverman Andersen Score (SAS) ≥ 5, or Respiratory Severity Score (RSS) ≥ 1.25]
  • Clinical decision for non-invasive respiratory support
  • Written parental consent

Exclusion criteria

Exclusion Criteria:

  • Surrogate deliveries
  • Major congenital or chromosomal anomalies
  • Prior intubation or receipt of surfactant
  • Known or suspected hypoxic ischemic encephalopathy (HIE)
  • Known or suspected neuromuscular disorder
  • Unanticipated survival
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
422 participants (estimated)

Study arms

  • Experimental
    Prophylactic Surfactant

    A single dose of surfactant (Curosurf) will be given via Surfactant Administration Through Laryngeal or Supraglottic Airways (SALSA). Infants who receive SALSA will remain on non-invasive respiratory support (Continuous Positive Airway Pressure).

    Procedure: Surfactant Administration Through Laryngeal or Supraglottic Airway (SALSA)

  • Active comparator
    Expectant Management (CPAP)

    For participating infants randomly assigned to receive continuation of non-invasive respiratory support, they will remain on continuous positive airway pressure (CPAP).

    Procedure: Continuous Positive Airway Pressure (CPAP)

Interventions

  • ProcedureSurfactant Administration Through Laryngeal or Supraglottic Airway (SALSA)

    A single dose of surfactant will be given via Surfactant Administration Through Laryngeal or Supraglottic Airways (SALSA). A supraglottic airway device will be used as a standardized procedure for surfactant administration via SALSA using an AirLife Air-Q.

  • ProcedureContinuous Positive Airway Pressure (CPAP)

    Infants to receive continuation of non-invasive respiratory support will remain on continuous positive airway pressure (CPAP).

06

What researchers measure

Primary outcomes

  1. Difference in Ranked Composite of Morbidities

    Determine if there is a difference in ranked composite of morbidities including death, development of pneumothorax/ pulmonary air leaks, Respiratory Severity Score (RSS), time to initial feeding, and LOS (length of hospital stay) between the treatment and control groups using a linked count of participants who fall within each prespecified rank.

    Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.

Secondary outcomes

  1. Length of Hospital Stay

    Length of hospital stay (LOS), days.

    Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.

Other outcomes

  1. Time to Parent Bonding

    Time to parent bonding from initial parent skin-to-skin contact.

    Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.

  2. Duration of Mechanical Ventilation

    Total duration of mechanical ventilation (MV) with endotracheal tube, days.

    Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.

  3. Duration of Continuous Positive Airway Pressure

    Total duration of Continuous Positive Airway Pressure (CPAP), days.

    Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.

  4. Duration of Non-Invasive Respiratory Support

    Duration of non-invasive respiratory support with positive pressure and/or high flow, days.

    Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.

  5. Oxygen Administration

    Oxygen administration requirements for Fraction of Inspired Oxygen (FiO2).

    Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.

  6. RSS Score at 24 hours of age

    Respiratory Severity Score (RSS)

    Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.

  7. Surfactant Administration

    Surfactant administration (additional dose administered to infants randomized to receive surfactant or any surfactant to infants receiving expectant CPAP management).

    Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.

  8. Time to Initial Feed

    Time to initial breastfeeding (including dry or nutritive) or oral feeding.

    Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.

  9. Time to Full Feeds

    Time to full feeds i.e. no parenteral nutrition.

    Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.

  10. Incidence of Pneumothorax

    Incidence of pneumothorax/ pulmonary air leaks.

    Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.

  11. Incidence of Respiratory Failure

    Defined as any of the following: Respiratory Severity Score (RSS) \>2.1, Silverman Andersen (SAS) ≥6, Respiratory acidosis, severe apnea

    Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.

  12. Incidence of Late Onset Sepsis

    Incidence of late onset sepsis.

    Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.

  13. Maternal Length of Stay

    Maternal total length of stay.

    Time frame: From hospital admission to study completion at hospital discharge after birth.

  14. Feeds at discharge

    Breastfeeding at time of discharge (yes/no).

    Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.

  15. Parent-Infant Separation

    Time to parental skin-to-skin contact

    Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.

07

Study locations

3 sites
08

References and documents

Publications

  • Ho JJ, Subramaniam P, Davis PG. Continuous positive airway pressure (CPAP) for respiratory distress in preterm infants. Cochrane Database Syst Rev. 2020 Oct 15;10(10):CD002271. doi: 10.1002/14651858.CD002271.pub3. PubMed 33058208 ↗
  • Polin RA, Carlo WA; Committee on Fetus and Newborn; American Academy of Pediatrics. Surfactant replacement therapy for preterm and term neonates with respiratory distress. Pediatrics. 2014 Jan;133(1):156-63. doi: 10.1542/peds.2013-3443. Epub 2013 Dec 30. PubMed 24379227 ↗
  • Dargaville PA, Kamlin COF, Orsini F, Wang X, De Paoli AG, Kanmaz Kutman HG, Cetinkaya M, Kornhauser-Cerar L, Derrick M, Ozkan H, Hulzebos CV, Schmolzer GM, Aiyappan A, Lemyre B, Kuo S, Rajadurai VS, O'Shea J, Biniwale M, Ramanathan R, Kushnir A, Bader D, Thomas MR, Chakraborty M, Buksh MJ, Bhatia R, Sullivan CL, Shinwell ES, Dyson A, Barker DP, Kugelman A, Donovan TJ, Tauscher MK, Murthy V, Ali SKM, Yossuck P, Clark HW, Soll RF, Carlin JB, Davis PG; OPTIMIST-A Trial Investigators. Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome: The OPTIMIST-A Randomized Clinical Trial. JAMA. 2021 Dec 28;326(24):2478-2487. doi: 10.1001/jama.2021.21892. PubMed 34902013 ↗
  • Ramaswamy VV, Bandyopadhyay T, Abiramalatha T, Pullattayil S AK, Szczapa T, Wright CJ, Roehr CC. Clinical decision thresholds for surfactant administration in preterm infants: a systematic review and network meta-analysis. EClinicalMedicine. 2023 Jul 20;62:102097. doi: 10.1016/j.eclinm.2023.102097. eCollection 2023 Aug. PubMed 37538537 ↗
  • Ramaswamy VV, Abiramalatha T, Bandyopadhyay T, Boyle E, Roehr CC. Surfactant therapy in late preterm and term neonates with respiratory distress syndrome: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2022 Jul;107(4):393-397. doi: 10.1136/archdischild-2021-322890. Epub 2021 Oct 22. PubMed 34686533 ↗
  • Calevo MG, Veronese N, Cavallin F, Paola C, Micaglio M, Trevisanuto D. Supraglottic airway devices for surfactant treatment: systematic review and meta-analysis. J Perinatol. 2019 Feb;39(2):173-183. doi: 10.1038/s41372-018-0281-x. Epub 2018 Dec 5. PubMed 30518796 ↗
  • Lockyear C, Coe K, Greenberg RG, Clark RH, Aleem S. Trends in morbidities of late preterm infants in the neonatal intensive care unit. J Perinatol. 2023 Nov;43(11):1379-1384. doi: 10.1038/s41372-023-01705-5. Epub 2023 Jul 1. PubMed 37393396 ↗
  • Katheria A, Ines F, Banerji A, Hopper A, Uy C, Chundu A, Coughlin K, Hutson S, Morales A, Sauberan J, Poeltler D, Dorner R, Rich W, Finer N. Caffeine and Less Invasive Surfactant Administration for Respiratory Distress Syndrome of the Newborn. NEJM Evid. 2023 Dec;2(12):EVIDoa2300183. doi: 10.1056/EVIDoa2300183. Epub 2023 Nov 21. PubMed 38320499 ↗
  • Jackson W, Taylor G, Bamat NA, Zimmerman K, Clark R, Benjamin DK, Laughon MM, Greenberg RG, Hornik CP. Outcomes associated with surfactant in more mature and larger premature infants with respiratory distress syndrome. J Perinatol. 2020 Aug;40(8):1171-1177. doi: 10.1038/s41372-020-0625-1. Epub 2020 Feb 20. PubMed 32080333 ↗
  • Berger DS, Garg B, Penfield CA, Caughey AB. Respiratory distress syndrome is associated with increased morbidity and mortality in late preterm births. Am J Obstet Gynecol MFM. 2024 Jun;6(6):101374. doi: 10.1016/j.ajogmf.2024.101374. Epub 2024 Apr 5. PubMed 38583712 ↗
  • Olivier F, Nadeau S, Caouette G, Piedboeuf B. Association between Apnea of Prematurity and Respiratory Distress Syndrome in Late Preterm Infants: An Observational Study. Front Pediatr. 2016 Sep 26;4:105. doi: 10.3389/fped.2016.00105. eCollection 2016. PubMed 27725928 ↗
  • Consortium on Safe Labor; Hibbard JU, Wilkins I, Sun L, Gregory K, Haberman S, Hoffman M, Kominiarek MA, Reddy U, Bailit J, Branch DW, Burkman R, Gonzalez Quintero VH, Hatjis CG, Landy H, Ramirez M, VanVeldhuisen P, Troendle J, Zhang J. Respiratory morbidity in late preterm births. JAMA. 2010 Jul 28;304(4):419-25. doi: 10.1001/jama.2010.1015. PubMed 20664042 ↗
  • Spong CY, Mercer BM, D'Alton M, Kilpatrick S, Blackwell S, Saade G. Timing of indicated late-preterm and early-term birth. Obstet Gynecol. 2011 Aug;118(2 Pt 1):323-333. doi: 10.1097/AOG.0b013e3182255999. PubMed 21775849 ↗

Individual participant data

Plan to share: Yes — Individual participant data, particularly data that underlie the results reported in this article after deidentification will be available with other researchers, including data dictionaries for meta-analysis.

Supporting information: Study protocol

Time frame: Beginning 6 months and ending 36 months following article publication.

Access criteria: Data and publication are available at http://clinicaltrials.gov

Data sharing details ↗ · clinicaltrials.gov

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2030, 61 months after the start.

Of 155 non-industry interventional studies with no phase under Pulmonary Atelectasis, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 24. This study's planned 61 months is above that.

Counting every sponsor, half of 157 studies reached it within 11 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 16, 2025
StartActual
Nov 20, 2025
Primary completionEst.
Dec 31, 2030
CompletionEst.
Jun 30, 2031
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07176117
Lead sponsor
Sharp HealthCare
Collaborators
Chiesi USA, Inc.
Responsible party
Anup Katheria, M.D. (Principal Investigator, Sharp HealthCare) — Principal investigator
First posted
Sep 16, 2025
Start date
Nov 20, 2025
Primary completion
Dec 31, 2030 (estimated)
Completion
Jun 30, 2031 (estimated)
Last update
Jul 13, 2026

Study contacts

Anup Katheria, MD
principal investigator · Sharp HealthCare

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion